Evidence map›Paper›PMID 16292516›Full record

ArticleRheumatology international2006

All-trans-retinoic acid suppresses interferon-gamma and tumor necrosis factor-alpha; a possible therapeutic agent for rheumatoid arthritis.

Yuji Nozaki, Chise Tamaki, Toshiaki Yamagata, Masafumi Sugiyama, Shinya Ikoma, Koji Kinoshita, Masanori Funauchi

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01667263 (The Combination of Oral All-trans Retinoic Acid and Danazol vs Danazol as Second-line Treatment in Adult Immune Thrombocytopenia), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01667263 phase2completednot on this mapstarted 2012, after this paper: background citation

The Combination of Oral All-trans Retinoic Acid and Danazol vs Danazol as Second-line Treatment in Adult Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial

TypeinterventionalSponsorPeking University People's HospitalRan2012 to 2017Enrolled130ConditionsAutoimmune ThrombocytopeniaArmsAll-trans retinoic acid, Danazol
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Animals : an open access journal from MDPI · 2026
    Article
  3. Article
  4. Dietary Sources, Sex, and rs5888 (International journal of molecular sciences · 2023
    Observational
  5. Myosin light chain kinase is a potential target for hypopharyngeal cancer treatment.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020
    Article
  6. Protective effect and mechanism of IL-10 on renal ischemia-reperfusion injury.Laboratory investigation; a journal of technical methods and pathology · 2019
    Article
  7. Review
  8. The pathological role of IL-18Rα in renal ischemia/reperfusion injury.Laboratory investigation; a journal of technical methods and pathology · 2015
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yuji NozakiDepartment of Nephrology and Rheumatology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Osaka, Japan.
Chise Tamaki
Toshiaki Yamagata
Masafumi Sugiyama
Shinya Ikoma
Koji Kinoshita
Masanori Funauchi
Kindai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo study the effects of all-trans-retinoic acid (ATRA), we determined the proliferation and cytokine production by peripheral blood mononuclear cells (PBMCs) and CD4+ T cells in healthy volunteers and patients with rheumatoid arthritis (RA), and explored the possibility of using ATRA as a therapeutic agent for autoimmune diseases.

methodsProliferation of these cells was determined by modified MTT assay, and expression of CC chemokine receptors 4 (CCR4) and CCR5 was determined by flow cytometry. Production and expression of interferon (IFN)-gamma, interleukin (IL)-2, IL-4, and tumor necrosis factor (TNF)-alpha was determined by Enzyme-Linked Immunosorbent Assay (ELISA) and reverse transcription-polymerase chain reaction (RT-PCR). The presence of STAT6 protein was determined by Western blot analysis.

resultsATRA did not affect the proliferation or production of IL-2 and IL-4. We did not detect STAT6 protein, and saw no evidence of the differentiation of PBMCs to Th1 or Th2 cells. In contrast, ATRA suppressed the production of IFN-gamma and TNF-alpha significantly. There were no significant differences between the healthy volunteers and RA patients.

conclusionsATRA was demonstrated to affect the cytokine production of IFN-gamma and TNF-alpha. ATRA might be useful in the treatment of autoimmune diseases such as RA.

Indexed as

AdolescentAdultAgedAntirheumatic AgentsArthritis, RheumatoidCell DifferentiationCell ProliferationCells, CulturedCytokinesHumansInterferon-gammaLeukocytes, MononuclearMiddle AgedReceptors, CCR4Receptors, CCR5Receptors, ChemokineAntirheumatic AgentsCCR4 protein, humanCytokinesInterferon-gammaReceptors, CCR4Receptors, CCR5Receptors, ChemokineRNA, MessengerSTAT6 protein, humanSTAT6 Transcription FactorTNF protein, humanTretinoinTumor Necrosis Factor-alpha

Identifiers

PMID16292516
OpenAlexW2090887381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.